G-CSF Omission for Breast Cancer

(REaCT-OGF Trial)

Recruiting in Palo Alto (17 mi)

Overseen by Xinni Song

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Recruiting

Sponsor: Ottawa Hospital Research Institute

Must be taking: G-CSF

Disqualifiers: Metastatic cancer, Hypersensitivity, others

No Placebo Group

Prior Safety Data

Approved in 2 Jurisdictions

Trial Summary

What is the purpose of this trial?

This trial is testing whether breast cancer patients can safely skip a medication during part of their chemotherapy. This medication helps with white blood cell recovery but can cause painful side effects. The study aims to see if omitting this medication can improve patients' quality of life without increasing infection risks.

Do I have to stop taking my current medications for this trial?

The trial information does not specify whether you need to stop taking your current medications. It focuses on whether or not to use G-CSF during a specific chemotherapy treatment.

What data supports the effectiveness of the drug G-CSF for breast cancer?

Research shows that G-CSF helps protect the bone marrow during chemotherapy, allowing for higher doses of cancer drugs like Taxol, which can improve treatment effectiveness. It also reduces the risk of febrile neutropenia (a serious drop in white blood cells that can lead to infection) during chemotherapy, making it a valuable supportive drug in cancer treatment. ^{1 2 3 4 5}

Is G-CSF generally safe for humans?

G-CSF (Granulocyte Colony-Stimulating Factor) is generally considered safe for humans, but it can cause side effects like bone pain. Studies have shown that it helps prevent complications like neutropenia (low white blood cell count) in cancer patients, which can reduce the risk of infections. ^{1 2 5 6 7}

How does omitting G-CSF in breast cancer treatment differ from other treatments?

Omitting G-CSF (a drug that helps boost white blood cell production) in breast cancer treatment is unique because it avoids the need for this additional medication, which is typically used to prevent low white blood cell counts during chemotherapy. This approach may reduce costs and side effects like bone pain, while still effectively managing the cancer with chemotherapy alone. ^{2 3 5 8 9}

Research Team

Xinni Song

Principal Investigator

Ottawa Hospital Research Institute

Eligibility Criteria

This trial is for early-stage or locally-advanced breast cancer patients who are about to receive DD-AC/T chemotherapy and need drugs to prevent infection due to low white blood cell counts. Participants must be able to consent and complete questionnaires in English or French, but can't join if they have metastatic cancer, past severe reactions to G-CSF, recent chemo within 5 years, or other serious health issues.

Inclusion Criteria

Able to provide verbal consent

I can complete questionnaires in English or French.

I am getting specific chemotherapy for breast cancer and need medicine to prevent infection.

Exclusion Criteria

Patients with uncontrolled inter-current illness that would limit compliance with study requirements or other significant diseases or disorders that, in the investigator's opinion, would exclude the subject from participating in the study

You are allergic to filgrastim or pegfilgrastim.

I have had chemotherapy in the past 5 years.

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Chemotherapy Treatment

Participants receive 4 cycles of adriamycin and cyclophosphamide followed by 4 cycles of paclitaxel using a dose-dense schedule

16 weeks

8 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment, including incidence of treatment-related hospitalizations and ER visits

4 weeks

Treatment Details

Interventions

• Granulocyte Colony-Stimulating Factor (G-CSF) (Cytokine)
• Omission of Granulocyte Colony-Stimulating Factor (G-CSF) (Cytokine)

Trial Overview The study is testing whether it's safe for breast cancer patients on the paclitaxel part of their DD-AC/T chemotherapy regimen to skip taking G-CSF—a drug usually given to boost white blood cells and prevent infections. Patients will either continue with G-CSF as usual or go without it during this phase of treatment.

Participant Groups

Group I: Omission of G-CSF Experimental Treatment 1 Intervention

Omission of G-CSF injections after each cycle of paclitaxel chemotherapy.

Group II: Receive G-CSF Active Control 1 Intervention

Receive G-CSF injections (either filgrastim or pegfilgrastim) after each cycle of paclitaxel chemotherapy.

Who Is Running the Clinical Trial?

Ottawa Hospital Research Institute

Lead Sponsor

Trials

585

Recruited

3,283,000+

Dr. Kathleen Gartke

Ottawa Hospital Research Institute

Chief Medical Officer

MD, University of Ottawa

Dr. Rebecca Auer

Ottawa Hospital Research Institute

Chief Executive Officer

MD, Memorial Sloan-Kettering Cancer Centre

Findings from Research

In a study of 47 ovarian cancer patients, using flexible dosing of granulocyte colony-stimulating factor (G-CSF) allowed for maintaining higher doses of taxol, which is associated with improved treatment efficacy, in 81% of patients.

The approach of increasing G-CSF dosage instead of reducing taxol after episodes of febrile neutropenia helped prevent further complications and may lower the risk of recurrence of neutropenia, suggesting that flexible G-CSF dosing could enhance the effectiveness of taxol therapy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Flexible granulocyte colony-stimulating factor dosing in ovarian cancer patients who receive dose-intense taxol therapy. Link, CJ., Bicher, A., Kohn, EC., et al.[2021]

In a study involving 36 women with metastatic breast cancer, the use of recombinant granulocyte-colony stimulating factor (rGCSF) as primary prophylaxis effectively reduced the incidence of febrile neutropenia to 14% during chemotherapy with docetaxel and doxorubicin.

The treatment was found to be safe, with common side effects including leukocytosis and bone pain, but it did not lead to any chemotherapy dose reductions, and patients reported improved emotional functioning and reduced pain.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Safety and efficacy study of the recombinant granulocyte colony-stimulating factor for prevention of neutropenia and neutropenia-related complications in women with metastatic breast cancer receiving docetaxel/doxorubicin]. Liutkauskiene, S., Sveikata, A., Juozaityte, E., et al.[2018]

In a study of 61 early breast cancer patients treated with accelerated paclitaxel without routine prophylactic GCSF, 69% did not require GCSF, indicating that it may not be necessary for all patients.

The treatment was safe, with no cases of neutropenic sepsis, and only a small percentage (10%) requiring secondary GCSF for severe neutropenia, suggesting that avoiding GCSF can reduce costs and side effects without compromising patient safety.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Routine prophylactic granulocyte colony stimulating factor (GCSF) is not necessary with accelerated (dose dense) paclitaxel for early breast cancer. Arnedos, M., Sutherland, S., Ashley, S., et al.[2015]

The study evaluated the safety and efficacy of recombinant granulocyte colony-stimulating factor (rG-CSF) in preventing neutropenia-related complications in 50 patients with metastatic breast cancer undergoing chemotherapy, showing that rG-CSF is effective in reducing the incidence of febrile neutropenia.

Despite some adverse events, including leukocytosis and bone pain, rG-CSF demonstrated a favorable safety profile and significantly decreased the risk of severe neutropenia, indicating its potential as a supportive treatment during myelosuppressive chemotherapy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

An open-label multicenter safety, tolerability, and efficacy study of recombinant granulocyte colony-stimulating factor in the prevention of neutropenic complications in breast cancer patients. Sveikata, A., Liutkauskienė, S., Juozaitytė, E., et al.[2018]

In a study of 56 patients with metastatic breast cancer who had previously been treated with anthracyclines, docetaxel showed a high overall response rate of 53%, indicating its effectiveness even in challenging cases.

The use of prophylactic granulocyte colony-stimulating factor significantly reduced severe neutropenia and neutropenic fever, while lower rates of fluid retention syndrome were observed with dexamethasone, suggesting that these supportive treatments can help manage docetaxel's side effects.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study. Ferraresi, V., Milella, M., Vaccaro, A., et al.[2019]

A systematic review of 61 randomized controlled trials involving over 9,000 patients showed that granulocyte colony-stimulating factor (G-CSF) significantly reduces all-cause mortality in patients receiving chemotherapy, with a relative risk of 0.93.

The most substantial mortality reduction was noted in studies using dose-dense chemotherapy schedules, indicating that G-CSF support can enhance treatment effectiveness and safety in cancer patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Lyman, GH., Dale, DC., Culakova, E., et al.[2022]

In a study of 1447 chemotherapy patients, initiating G-CSF (filgrastim) within 24-72 hours post-chemotherapy was found to be effective and safe for preventing chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN).

Patients who received G-CSF on the same day as chemotherapy had similar outcomes to those who followed the recommended guidelines, but those who started treatment late (more than 72 hours after chemotherapy) had worse odds of experiencing severe CIN episodes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated "same-day" ( 72 h): findings from the MONITOR-GCSF study. Ludwig, H., Gascón, P., Bokemeyer, C., et al.[2020]

References

1. United States pubmed.ncbi.nlm.nih.gov

Flexible granulocyte colony-stimulating factor dosing in ovarian cancer patients who receive dose-intense taxol therapy. [2021]

2. United States pubmed.ncbi.nlm.nih.gov

Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. [2017]

3. Switzerland pubmed.ncbi.nlm.nih.gov

Recombinant human granulocyte colony-stimulating factor in the management of cancer patients: five years on. [2018]

4. Switzerland pubmed.ncbi.nlm.nih.gov

[Safety and efficacy study of the recombinant granulocyte colony-stimulating factor for prevention of neutropenia and neutropenia-related complications in women with metastatic breast cancer receiving docetaxel/doxorubicin]. [2018]

5. Netherlands pubmed.ncbi.nlm.nih.gov

Routine prophylactic granulocyte colony stimulating factor (GCSF) is not necessary with accelerated (dose dense) paclitaxel for early breast cancer. [2015]

6. Switzerland pubmed.ncbi.nlm.nih.gov

An open-label multicenter safety, tolerability, and efficacy study of recombinant granulocyte colony-stimulating factor in the prevention of neutropenic complications in breast cancer patients. [2018]

7. United States pubmed.ncbi.nlm.nih.gov

Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study. [2019]

8. England pubmed.ncbi.nlm.nih.gov

The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. [2022]

9. Germany pubmed.ncbi.nlm.nih.gov

Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated "same-day" ( 72 h): findings from the MONITOR-GCSF study. [2020]